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Although there have been progressive advancements in the 
life sciences since the beginning of the 21st Century, basic 
medical sciences generally fail to be efficiently translated 
into clinical research and ultimately into clinical practice. 
Translational medicine has become a fashionable term de-
scribing the inclination of basic science and clinical re-
searchers to ultimately help patients through facilitating the 
incorporation of basic research findings into clinical prac-
tice (Zerhouni, 2005). 
The development of translational medicine in recent 
years has been rapid—focusing on a new medical research 
model advocating “patient-centered” clinical work. Starting 
with clinical questions regarding patient problems, con-
ducting basic research, and then turning the results of basic 
research quickly into clinical applications to improve clini-
cal care is the heart of this new model. Translational medi-
cine is an emerging area comprising multidisciplinary re-
search from both basic and clinical medical sciences which 
can be summarized by both the “bench-to-bedside” and 
“bedside-to-bench” concepts (Albani and Prakken, 2009). 
This concept requires close collaboration between clinical 
and basic science researchers across departments and insti-
tutions. This means translational medicine is not a tradition-
al one-way (e.g., “bench-to-bedside”), but an open, two-way 
path. Labora- tory research results are not only quickly ap-
plied, but clinical practice and clinical problems give timely 
feedback to the laboratory in order to fine-tune and contin-
uously improve the research process. In this article, we will 
play a special emphasis on translational medicine at our 
home institution, Peking Union Medical College Hospital 
(PUMCH). 
THE TRADITION OF TRANSLATIONAL 
MEDICINE AT PUMCH 
The concept of translational medicine is not new at  
PUMCH. From the beginning, PUMCH has adhered to the 
concept of translational medicine by closely integrating 
clinical and basic science research. Not only is this repre-
sented in the unity of the hospital and medical school, but 
also the unity of clinical practice and basic medical research 
which has made PUMCH and Peking Union Medical Col-
lege (PUMC) the cradles of translational medicine in China.  
PUMCH has a long history and a formidable tradition in 
translational medicine research. In the past, many professors 
of PUMCH were not only distinguished physicians, but 
were also basic science researchers in their own right. For 
example, Prof. Shihao Liu, a renowned endocrinologist as 
well as a professor of biochemistry, devoted his life’s work 
to the establishment and development of endocrine disci-
plines in China. Prof. Liu recognized that endocrinology 
plays a very important role in both clinical medicine and 
basic science. His most important contribution was a study 
on calcium and phosphorus metabolism performed with his 
colleague (and fellow endocrinologist) Xianyi Zhu. Togeth-
er, their studies in the 1940s on calcium and phosphorus 
metabolism in osteomalacia proved that osteomalacia was 
mainly caused by vitamin D deficiency, and also proposed 
the first concept of renal osteodystrophy, as well as pub-
lished the “Treatment of Renal Osteodystrophy with Dihy-
drotachysterol (A.T.10) and Iron” in Science (Liu and Chu, 
1942).  
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THE ADVANTAGES OF TRANSLATIONAL 
MEDICINE AT PUMCH 
Outstanding clinical environment 
Translational Medicine should be regarded as a two-way 
road which aims to bridge the gap and build the platform 
between basic and clinical research. To build an outstanding 
translational medicine team, it is not enough to have a good 
basic science research team, but a good clinical science 
team with an excellent clinical environment is crucial as 
well.  
PUMCH and its affiliated medical college were founded 
by the Rockefeller Foundation in 1921. The hospital has 
gathered notable physicians, medical professionals and sci-
entific researchers of various specialties since, and has 
maintained its leading position as one of the top-ranked 
hospitals in China for over 90 years. For example, PUMCH 
currently hosts the Chinese Academy of Medical Sciences 
(CAMS) on its campus. On a noted list of China’s best hos-
pitals, the comprehensive clinical strength of PUMCH 
ranked the highest. Every year there are more than 200 mil-
lion outpatient visits and over 50,000 hospitalized patients. 
Meanwhile, there are more than 60,000 outpatient visits in 
the Health Examination Center of PUMCH each year, 
which can be used as a normal control group for transla-
tional medical research.  
Given this immense volume of clinical encounters, 
PUMCH collects a very large amount of tissue and serum 
samples (more than 40,000 surgical specimens and 60,000 
blood specimens every year). PUMCH has a long history of 
preserving tissue samples, and some departments at 
PUMCH have their own tissue banks.  
At the same time, it is very important to have high quali-
ty and comprehensive medical records for medical research. 
Since the establishment of PUMCH, all medical records 
have been meticulously preserved, which can provide addi-
tional clinical data for translational medical research.  
Clinically-oriented medical research 
The core research principle at PUMCH is very similar to  
the philosophy of translational medicine. Translational 
medicine’s “patient-centered” clinical work model has been 
consistently advocated at PUMCH, and likely is a key rea-
son why PUMCH has maintained its position at the highest 
level of medicine in China. For example, Prof. Zhinan 
Zhang, in a recent article about research at PUMCH, has 
pointed out that “we should find problems from clinical 
practice and ask questions, (and) do further clinical analysis 
or experimental research to seek answers to solve clinical 
problems”. 
Solid foundation of medical research 
The development of translational medicine must depend on 
a solid foundation of medical research. Currently, there are 
25 professionals approved to make clinical experiments by 
the Chinese State Food and Drug Administration at 
PUMCH. PUMCH also has many high-level institutes of 
basic medical research, such as the International Clinical 
Pharmacology Center, and the Key Laboratory of Endocri-
nology. This existing infrastructure has enabled PUMCH to 
actively pursue translational medicine research. Finally, 
PUMCH is in close cooperation with the institutes of Path-
ogen Biology and Basic Medical Sciences in the Chinese 
Academy of Medical Sciences, as well as the Institute of 
Materia Medica of PUMC. All of these institutions help 
promote the development of basic science research and 
translational medical research at PUMCH. 
THE STATUS OF TRANSLATIONAL  
MEDICINE AT PUMCH 
Even though PUMCH has a plethora of basic science and 
clinical resources, recent steps have improved adoption of 
translational medicine. A first step toward the promotion of 
translational medicine at PUMCH was to conduct joint pro-
jects with the Institute of Basic Medical Sciences of the 
Chinese Academy of Medical Sciences. All projects in-
cluded two research arms, basic and clinical, which worked 
together closely. PUMCH also co-organized the “Clinical 
Research Centre of Pathogen(s)” with the Institute of Path-
ogen Biology of the Chinese Academy of Medical Sciences 
to look into newly emergent pathogens. 
In addition, PUMCH has held multiple international fo-
rums on translational medical research. Four forums specif-
ic to translational medical research were held from 2007 to 
2011. These forums built a framework for communication 
between clinical and basic science researchers at PUMCH 
and around the world. Additionally, PUMCH was a 
co-organizer of the “Sino-American Symposium on Clinical 
and Translational Research” held in Beijing in June 2010. 
This meeting aimed at gathering a broader audience of cli-
nicians, basic and clinical science researchers, ethicists and 
health care officials from hospitals, academia and govern-
mental agencies involved in human subject research and/or 
multi-national clinical trials. A number of important themes 
relevant to bilateral collaborations between the USA and 
China were discussed (Guan and Chen, 2011). 
Another milestone was the initiation of the PUMCH 
Translational Medicine Center (PUMCH-TMC), launched 
in Beijing on September 16, 2010 with the support of Min-
istry of Health and Ministry of Science and Technology of 
China. The PUMCH-TMC is a translational medical re-
search platform involving 54 academicians based in hospital 
and existing medical research institutions. The objective of 
the PUMCH-TMC is to become a national center for trans-
lational medicine, and to assist in clinical care at PUMCH 
(Zhao, 2011).  
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The directors of the PUMCH-TMC recognized that 
translational medicine is not only a concept, but requires 
practical action. For such, the PUMCH-TMC has identified 
major translational medicine research topics to focus on, 
including: regenerative therapy using stem cells for central 
nervous system diseases, the integrated study of the clinical 
features and molecular mechanisms of pancreatic cancer, 
HIV/AIDS, chronic metabolic diseases such as diabetes, 
rheumatologic diseases, and the diagnostic and therapeutic 
use of allergens. Finally, the PUMCH-TMC has recently 
been working with the University of California in San Fran-
cisco to work on international translational medicine col-
laborations. 
THE FUTURE GOALS OF TRANSLATIONAL 
MEDICINE AT PUMCH 
The future of translational medicine at PUMCH has short-,  
mid- and long-term goals.  
Short-term goals: (i) To examine ongoing clinical and 
basic science research projects and use the PUMCH-TCH 
resources to further potential translational work. (ii) To con-
tinue to enlarge the human tissue and blood bank at 
PUMCH, and make it more accessible for translational re-
search. 
Mid-term goals: A translational medicine platform 
should be created to provide consulting services and re-
search technique support to interested individuals and insti-
tutes. All projects initiated by this platform should be con-
ducted within the PUMCH-TMC. The platform should have 
the following functions: provide consulting services and 
technique support to researchers, create more collaborations 
and partnerships, as well as provide lectures for post- 
graduate education. 
Long-term goals: An international translational medicine 
institute will be created. This international translational 
medicine institute will become a high-end platform for 
promoting international translational medicine research 
programs. 
CONCLUSION 
Translational medical research aims to provide an oppor-
tunity for patients to benefit from the closer cooperation of 
the basic and clinical sciences. Promising collaborative 
translational research as illustrated in this review is an on-
going process at PUMCH. The extensive clinical and basic 
medical research resources of PUMCH provide a robust 
platform for translational medicine research programs. With 
consistent effort, the PUMCH-TMC aims to become an 
international platform for supporting translational medicine 
research. 
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